GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aerie Pharmaceuticals Inc (NAS:AERI) » Definitions » Total Inventories

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Total Inventories : $46.8 Mil (As of Sep. 2022)


View and export this data going back to 2013. Start your Free Trial

What is Aerie Pharmaceuticals Total Inventories?

Aerie Pharmaceuticals's total inventories for the quarter that ended in Sep. 2022 was $46.8 Mil. Aerie Pharmaceuticals's average total inventories from the quarter that ended in Jun. 2022 to the quarter that ended in Sep. 2022 was $46.9 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Aerie Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Sep. 2022 was $-5.84.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Aerie Pharmaceuticals's Days Inventory for the three months ended in Sep. 2022 was 617.44.

Inventory Turnover measures how fast the company turns over its inventory within a year. Aerie Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2022 was 0.15.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Aerie Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2022 was 1.30.


Aerie Pharmaceuticals Total Inventories Historical Data

The historical data trend for Aerie Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerie Pharmaceuticals Total Inventories Chart

Aerie Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 10.11 21.05 27.06 40.41

Aerie Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.06 40.41 40.19 47.01 46.76

Aerie Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Aerie Pharmaceuticals  (NAS:AERI) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Aerie Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2022 is

Net-Net Working Capital Per Share (Q: Sep. 2022 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(172.464+0.75 * 73.881+0.5 * 46.762-539.572
-0-0)/49.3905
=-5.84

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Aerie Pharmaceuticals's Days Inventory for the three months ended in Sep. 2022 is calculated as:

Days Inventory=Average Total Inventories (Q: Sep. 2022 )/Cost of Goods Sold (Q: Sep. 2022 )*Days in Period
=46.8845/6.929*365 / 4
=617.44

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Aerie Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2022 ) / Average Total Inventories (Q: Sep. 2022 )
=6.929 / 46.8845
=0.15

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Aerie Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2022 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=46.8845 / 36.129
=1.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Aerie Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Aerie Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerie Pharmaceuticals (Aerie Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4301 Emperor Boulevard, Suite 400, Durham, NC, USA, 27703
Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.
Executives
Peter Frederick Lang officer: Chief Financial Officer AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Raj Kannan director, officer: Chief Executive Officer C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
Jeffrey Calabrese officer: Vice President of Finance AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Kathleen Mcginley officer: CHRO & VP, Corp Services 15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618
Christopher Staten officer: Interim CFO AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Casey C. Kopczynski officer: Chief Scientific Officer 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Peter J Mcdonnell director 2525 DUPONT DRIVE, IRVINE CA 92612
Gerald D. Cagle director 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Foresite Capital Fund Ii, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
David Hollander officer: Chief R&D Officer C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Richard J Rubino officer: Chief Financial Officer
Vicente Jr Anido director, officer: Chief Executive Officer 1621 BAYSIDE DR, CORONA DEL MAR CA 92625
Foresite Capital Management Iv, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iv, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Thomas A Mitro officer: President and COO 15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618